GrantCarltonLewisMD

Oncology • Savannah, GA

Hematology/Oncology Specialist at Summit Cancer Care

Join to view full profile

Dr. Lewis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lewis' full profile

Already have an account?

Office
225 Candler Dr
Suite 300
Savannah, GA 31405
Phone+1 912-354-6187

Fax+1 912-355-0596

Education & Training

Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Alabama Medical CenterResidency, Internal Medicine, 2003 - 2006
Mercer University School of MedicineClass of 2003

Certifications & Licensure

GA State Medical License 2006 - 2025
SC State Medical License 2009 - 2011
AL State Medical License 2004 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Start of enrollment: 2009 Jul 16
Completed
Phase 2
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

14 citations
Acute myelogenous leukemia patients are at low risk for invasive fungal infections after high-dose cytarabine consolidations and thus do not require prophylaxis.
Grant Lewis, Patricia Hall, Nihal Eisa, David L. DeRemer, Robin Dobbins
Acta Haematologica. 2010-11-12

Press Mentions

With This Grant Renewal Comes New Initiatives and Grant Aims to Further Expand Cancer Research to a Broader Population and Include Underserved Populations in Cancer Research:July 16th, 2019